KRN8602 (MX2-hydrochloride): An active new agent for the treatment of recurrent high-grade glioma

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2579-2584

  Clarke, Kerrie ^a   Basser, Russell L ^a   Underhill, Craig ^a   Mitchell, Peter ^a   Bartlett, Jane ^a   Cher, Lawrence ^a   Findlay, Michael ^a   Dalley, David ^a   Pell, Malcolm ^a   Byrne, Michael ^a   Geldard, Howard ^a   Hill, John S ^a   Maher, Darryl ^a   Fox, Richard M ^a   Green, Michael D ^a   Kaye, Andrew H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032766475     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2579     Document Type: Article

References (31)

1. Burger PC, Vogel FS, Green SB, et al: Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 56:1106-1111, 1985
2. Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980
3. Walker MD, Alexander E Jr, Hunt WE: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 49:333-343, 1978
4. Levin VA, Silver P, Hannigan J, et al: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324, 1990
5. Watanabe M, Komeshima N, Naito M, et al: Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells. Cancer Res 51:157-161, 1991
6. Sato Y, Eddy L, Hochstein P: Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602). Biochem Pharmacol 42:2283-2287, 1991
7. Izumoto S, Arita N, Hayakawa T, et al: Effect of MX2, a new morpholino anthracycline, against experimental brain tumors. Anticancer Res 10:735-739, 1990
8. Kabuto M, Kubota T, Kobayashi H, et al: The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution. Neurosurgery 37:471-477, 1995
9. Kabuto M, Kaye AH, Hill JS, et al: Antitumour effect of MX2, a new morpholino anthracycline against C6 glioma cells and its cytotoxic effect in combination with photodynamic therapy. J Clin Neuroscience 1:47-52, 1994
10. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 3:255-268, 1993
11. Castel JC, Caille JM: Imaging of irradiated brain tumours: Value of magnetic resonance imaging. J Neuroradiol 16:81-132, 1989
12. Dooms GC, Hecht S, Brant-Zawadzki M, et al: Brain radiation lesions: MR imaging. Radiology 158:149-155, 1986
13. Albert FK, Forsting M, Sartor K, et al: Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45-61, 1994
14. Clarke K, Basser RL, Maher D, et al: Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer. J Clin Oncol 16:2181-2187, 1998
15. Rajan B, Ross G, Lim CC, et al: Survival of patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosurea chemotherapy. Eur J Cancer 30A: 1809-1815, 1994
16. Huncharek M, Muscat J: Treatment of recurrent high grade astrocytoma: Results of a systematic review of 1,415 patients. Anticancer Res 18:1303-1311, 1998
17. Brandes AA, Fiorentino MV: The role of chemotherapy in recurrent malignant gliomas: An overview. Cancer Invest 14:551-559, 1996
18. Prados MD, Schold SC, Spence AM, et al: Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14:2316-2321, 1996
19. Chamberlain MC, Kormanik P: Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13:2066-2071, 1995
20. Newlands ES, O'Reilly SM, Glaser MG, et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A:2236-2241, 1996
21. Coley HM, Twentyman PR, Workman P: 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance [see comments]. Eur J Cancer 26:665-667, 1990
22. Watanabe M, Komeshima N, Nakajima S, et al: MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Cancer Res 48:6653-6657, 1988
23. Umezawa H, Nakajima S, Kawai H, et al: New morpholino anthracyclines, MX, MX2, and MY5. J Antibiot 40:1058-1061, 1987
24. Morgan DJ, Hill JS, Clarke K, et al: Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. Cancer Chemother Pharmacol 40:202-208, 1997
25. Focan C, Andrien JM, Closon MTh, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
26. Wood WC, Budman DR, Korzus AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
27. Jeremic B, Grujicic D, Jevremovic S, et al: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 10:1074-1077, 1992
28. Levin VA, Edwards MS, Wright DC: Modified procarbazine, CCNU and vincristine combination (PCV 3) in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-241, 1980
29. Sanson M, Ameri A, Monjour A, et al: Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study. Eur J Cancer 32A:2229-2235, 1996
30. Fine HA, Dear KBG, Loeffler JS, et al: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597, 1993
31. Hildebrand J, Sahmoud T, Mignolet F, et al: Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas: EORTC Brain Tumor Group. Neurology 44:1479-1483, 1994